COL3A1 expression in PCOS [74] as well as POI [75] suggest that Lnc-GULP1-2:1 (long non-coding RNA) could be used to alter COL3A1 expression, treating it as a therapeutic target. This evidence concerns the gene COL3A1 and polycystic ovary syndrome.